Renaissance Capital logo

UNCY News

Micro-cap kidney disease biotech Unicycive Therapeutics prices IPO at $5 low end

Unicycive Therapeutics logo

Unicycive Therapeutics, an early-stage biotech developing in-licensed therapies for kidney disease, raised $25 million by offering 5 million units at $5, the low end of the range of $5 to $6. Each unit consists of one share of common stock and four-fifths of a...read more

US IPO Week Ahead: Real estate, post-pandemic plays and more in a 15 IPO week

STVN

Updated Monday, 7/12. After a slow holiday week, 15 IPOs are scheduled to raise nearly $4 billion in the week ahead. A handful of SPACs should also price. Italian drug container supplier Stevanato Group (STVN) plans to raise $900...read more

Kidney disease biotech Unicycive Therapeutics adds warrants, increases deal size ahead of $40 million IPO

Unicycive Therapeutics logo

Unicycive Therapeutics, an early stage biotech developing in-licensed therapies for kidney disease, increased the proposed deal size for its upcoming IPO on Monday. The Los Altos, CA-based company now plans to raise $40 million by offering 6.7 million units...read more

US IPO Week Ahead: Billion-dollar deals come to market in a 17 IPO week

YMM

Updated Monday, 6/21/21. 17 IPOs are scheduled to raise $6.3 billion in the week ahead, led by two billion-dollar deals. Chinese freight platform Full Truck Alliance (YMM) plans to raise $1.5 billion at a $19.7 billion market cap....read more